Men with prostate cancer who are treated with androgen-suppressing GnRH analog drugs, are at markedly increased risk of osteoporosis and bone fractures compared with patients of similar age who are not taking these drugs. The longer a man is on a GnRH analog, the greater is his osteoporosis/fracture risk.